Molecular markers of carcinogenesis for risk stratification of individuals with colorectal polyps: A case-control study

Samir Gupta, Han Sun, Sang Yi, Joy Storm, Guanghua Xiao, Bijal A. Balasubramanian, Song Zhang, Raheela Ashfaq, Don C. Rockey

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Risk stratification using number, size, and histology of colorectal adenomas is currently suboptimal for identifying patients at increased risk for future colorectal cancer.Wehypothesized that molecular markers of carcinogenesis in adenomas, measured via immunohistochemistry, may help identify high-risk patients. To test this hypothesis, we conducted a retrospective, 1:1 matched case-control study (n=216; 46% female) in which cases were patients with colorectal cancer and synchronous adenoma and controls were patients with adenoma but no colorectal cancer at baseline or within 5 years of follow-up. In phase I of analyses, we compared expression of molecular markers of carcinogenesis in case and control adenomas, blind to case status. In phase II of analyses, patients were randomly divided into independent training and validation groups to develop a model for predicting case status. We found that seven markers [p53, p21, Cox-2, b-catenin (BCAT), DNA-dependent protein kinase (DNApkcs), survivin, and O6-methylguanine-DNA methyltransferase (MGMT)] were significantly associated with case status on unadjusted analyses, as well as analyses adjusted for age and advanced adenoma status (P < 0.01 for at least one marker component). When applied to the validation set, a predictive model using these seven markers showed substantial accuracy for identifying cases [area under the receiver operation characteristic curve (AUC), 0.83; 95% confidence interval (CI), 0.74-0.92]. A parsimonious model using three markers performed similarly to the sevenmarker model (AUC, 0.84). In summary, we found that molecular markers of carcinogenesis distinguished adenomas from patients with and without colorectal cancer. Furthermore, we speculate that prospective studies using molecular markers to identify individuals with polyps at risk for future neoplasia are warranted.

Original languageEnglish (US)
Pages (from-to)1023-1034
Number of pages12
JournalCancer Prevention Research
Volume7
Issue number10
DOIs
StatePublished - Oct 1 2014

Fingerprint

Polyps
Adenoma
Case-Control Studies
Carcinogenesis
Colorectal Neoplasms
Area Under Curve
DNA-Activated Protein Kinase
Catenins
Methyltransferases
Histology
Immunohistochemistry
Prospective Studies
Confidence Intervals
DNA
Neoplasms

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Molecular markers of carcinogenesis for risk stratification of individuals with colorectal polyps : A case-control study. / Gupta, Samir; Sun, Han; Yi, Sang; Storm, Joy; Xiao, Guanghua; Balasubramanian, Bijal A.; Zhang, Song; Ashfaq, Raheela; Rockey, Don C.

In: Cancer Prevention Research, Vol. 7, No. 10, 01.10.2014, p. 1023-1034.

Research output: Contribution to journalArticle

Gupta, Samir ; Sun, Han ; Yi, Sang ; Storm, Joy ; Xiao, Guanghua ; Balasubramanian, Bijal A. ; Zhang, Song ; Ashfaq, Raheela ; Rockey, Don C. / Molecular markers of carcinogenesis for risk stratification of individuals with colorectal polyps : A case-control study. In: Cancer Prevention Research. 2014 ; Vol. 7, No. 10. pp. 1023-1034.
@article{30a04bbcc4684240b803f5ffde32e83e,
title = "Molecular markers of carcinogenesis for risk stratification of individuals with colorectal polyps: A case-control study",
abstract = "Risk stratification using number, size, and histology of colorectal adenomas is currently suboptimal for identifying patients at increased risk for future colorectal cancer.Wehypothesized that molecular markers of carcinogenesis in adenomas, measured via immunohistochemistry, may help identify high-risk patients. To test this hypothesis, we conducted a retrospective, 1:1 matched case-control study (n=216; 46{\%} female) in which cases were patients with colorectal cancer and synchronous adenoma and controls were patients with adenoma but no colorectal cancer at baseline or within 5 years of follow-up. In phase I of analyses, we compared expression of molecular markers of carcinogenesis in case and control adenomas, blind to case status. In phase II of analyses, patients were randomly divided into independent training and validation groups to develop a model for predicting case status. We found that seven markers [p53, p21, Cox-2, b-catenin (BCAT), DNA-dependent protein kinase (DNApkcs), survivin, and O6-methylguanine-DNA methyltransferase (MGMT)] were significantly associated with case status on unadjusted analyses, as well as analyses adjusted for age and advanced adenoma status (P < 0.01 for at least one marker component). When applied to the validation set, a predictive model using these seven markers showed substantial accuracy for identifying cases [area under the receiver operation characteristic curve (AUC), 0.83; 95{\%} confidence interval (CI), 0.74-0.92]. A parsimonious model using three markers performed similarly to the sevenmarker model (AUC, 0.84). In summary, we found that molecular markers of carcinogenesis distinguished adenomas from patients with and without colorectal cancer. Furthermore, we speculate that prospective studies using molecular markers to identify individuals with polyps at risk for future neoplasia are warranted.",
author = "Samir Gupta and Han Sun and Sang Yi and Joy Storm and Guanghua Xiao and Balasubramanian, {Bijal A.} and Song Zhang and Raheela Ashfaq and Rockey, {Don C.}",
year = "2014",
month = "10",
day = "1",
doi = "10.1158/1940-6207.CAPR-14-0140",
language = "English (US)",
volume = "7",
pages = "1023--1034",
journal = "Cancer Prevention Research",
issn = "1940-6207",
publisher = "American Association for Cancer Research Inc.",
number = "10",

}

TY - JOUR

T1 - Molecular markers of carcinogenesis for risk stratification of individuals with colorectal polyps

T2 - A case-control study

AU - Gupta, Samir

AU - Sun, Han

AU - Yi, Sang

AU - Storm, Joy

AU - Xiao, Guanghua

AU - Balasubramanian, Bijal A.

AU - Zhang, Song

AU - Ashfaq, Raheela

AU - Rockey, Don C.

PY - 2014/10/1

Y1 - 2014/10/1

N2 - Risk stratification using number, size, and histology of colorectal adenomas is currently suboptimal for identifying patients at increased risk for future colorectal cancer.Wehypothesized that molecular markers of carcinogenesis in adenomas, measured via immunohistochemistry, may help identify high-risk patients. To test this hypothesis, we conducted a retrospective, 1:1 matched case-control study (n=216; 46% female) in which cases were patients with colorectal cancer and synchronous adenoma and controls were patients with adenoma but no colorectal cancer at baseline or within 5 years of follow-up. In phase I of analyses, we compared expression of molecular markers of carcinogenesis in case and control adenomas, blind to case status. In phase II of analyses, patients were randomly divided into independent training and validation groups to develop a model for predicting case status. We found that seven markers [p53, p21, Cox-2, b-catenin (BCAT), DNA-dependent protein kinase (DNApkcs), survivin, and O6-methylguanine-DNA methyltransferase (MGMT)] were significantly associated with case status on unadjusted analyses, as well as analyses adjusted for age and advanced adenoma status (P < 0.01 for at least one marker component). When applied to the validation set, a predictive model using these seven markers showed substantial accuracy for identifying cases [area under the receiver operation characteristic curve (AUC), 0.83; 95% confidence interval (CI), 0.74-0.92]. A parsimonious model using three markers performed similarly to the sevenmarker model (AUC, 0.84). In summary, we found that molecular markers of carcinogenesis distinguished adenomas from patients with and without colorectal cancer. Furthermore, we speculate that prospective studies using molecular markers to identify individuals with polyps at risk for future neoplasia are warranted.

AB - Risk stratification using number, size, and histology of colorectal adenomas is currently suboptimal for identifying patients at increased risk for future colorectal cancer.Wehypothesized that molecular markers of carcinogenesis in adenomas, measured via immunohistochemistry, may help identify high-risk patients. To test this hypothesis, we conducted a retrospective, 1:1 matched case-control study (n=216; 46% female) in which cases were patients with colorectal cancer and synchronous adenoma and controls were patients with adenoma but no colorectal cancer at baseline or within 5 years of follow-up. In phase I of analyses, we compared expression of molecular markers of carcinogenesis in case and control adenomas, blind to case status. In phase II of analyses, patients were randomly divided into independent training and validation groups to develop a model for predicting case status. We found that seven markers [p53, p21, Cox-2, b-catenin (BCAT), DNA-dependent protein kinase (DNApkcs), survivin, and O6-methylguanine-DNA methyltransferase (MGMT)] were significantly associated with case status on unadjusted analyses, as well as analyses adjusted for age and advanced adenoma status (P < 0.01 for at least one marker component). When applied to the validation set, a predictive model using these seven markers showed substantial accuracy for identifying cases [area under the receiver operation characteristic curve (AUC), 0.83; 95% confidence interval (CI), 0.74-0.92]. A parsimonious model using three markers performed similarly to the sevenmarker model (AUC, 0.84). In summary, we found that molecular markers of carcinogenesis distinguished adenomas from patients with and without colorectal cancer. Furthermore, we speculate that prospective studies using molecular markers to identify individuals with polyps at risk for future neoplasia are warranted.

UR - http://www.scopus.com/inward/record.url?scp=84907542968&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84907542968&partnerID=8YFLogxK

U2 - 10.1158/1940-6207.CAPR-14-0140

DO - 10.1158/1940-6207.CAPR-14-0140

M3 - Article

C2 - 25092825

AN - SCOPUS:84907542968

VL - 7

SP - 1023

EP - 1034

JO - Cancer Prevention Research

JF - Cancer Prevention Research

SN - 1940-6207

IS - 10

ER -